Sign Out
Treatment should be initiated by physicians experienced in the diagnosis and treatment of migraine.
Posology: The recommended dose is 120 mg galcanezumab injected subcutaneously once monthly, with a 240 mg loading dose as the initial dose.
Patients should be instructed to inject a missed dose as soon as possible and then resume monthly dosing.
Elderly (> 65 years): Galcanezumab has not been studied in elderly patients. No dose adjustment is required as the pharmacokinetics of galcanezumab are not affected by age.
Renal impairment/hepatic impairment: No dose adjustment is required in patients with mild to moderate renal impairment or hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of galcanezumab in children aged 6 to 18 years have not yet been established. No data are available.
There is no relevant use of galcanezumab in children below the age of 6 years for the prevention of migraine.
Method of administration: Subcutaneous use.
A patient may self-inject galcanezumab by following the Instructions for Use under Cautions for Usage. Galcanezumab is to be injected subcutaneously in the abdomen, thigh, back of the upper arm, or in the gluteal region. After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate. Comprehensive instructions for administration are given in the Package Leaflet.
